Drugs / ALEXTATUG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04244552 | Feb 2020 → Nov 2023 | acral lentiginous melanoma, colorectal cancer, esophageal squamous cell carcinoma, fallopian tube carcinoma +7 | Atreca, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALEXTATUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314808 ↗ |
| Known as | ATRC-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04244552 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314808 ↗ |